USP8: a novel therapeutic target for Cushing's disease. (Q38545050)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

review article

1 reference

title

USP8: a novel therapeutic target for Cushing's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

author name string

Fangfang Jian

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

Liuguan Bian

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

Qingfang Sun

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

publication date

11 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

292-296

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Late recurrences of Cushing's disease after initial successful transsphenoidal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Gamma Knife surgery for Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Cabergoline monotherapy in the long-term treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

The molecular pathogenesis of corticotroph tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Mutations in the deubiquitinase gene USP8 cause Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Recurrent gain-of-function USP8 mutations in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

14-3-3-dependent inhibition of the deubiquitinating activity of UBPY and its cancellation in the M phase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

The Usp8 deubiquitination enzyme is post-translationally modified by tyrosine and serine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

UBPY: a growth-regulated human ubiquitin isopeptidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Ubiquitination in disease pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

The ubiquitin code and its decoding machinery in the endocytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

A genomic and functional inventory of deubiquitinating enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Deubiquitinating enzymes as novel anticancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Targeting the EGFR pathway for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

EGFR-mutated lung cancer: a paradigm of molecular oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

EGFR antagonists in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

C-MET as a new therapeutic target for the development of novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Gefitinib: a review of its use in adults with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

USP8 is a novel target for overcoming gefitinib resistance in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S12020-015-0682-Y

MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality.

21 January 2018

1 reference

12 December 2020

Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

1 reference

12 December 2020

BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function

1 reference

12 December 2020

Long-term results of stereotactic radiosurgery in secretory pituitary adenomas

1 reference

12 December 2020

Medical treatment of prolactinomas

1 reference

12 December 2020

Ketoconazole in Cushing's disease: is it worth a try?

1 reference

12 December 2020

Localization of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFr) in Human Pituitary Adenomas and Nontumorous Pituitaries: An Immunocytochemical Study

1 reference

12 December 2020

Therapeutic strategies for the treatment of multiple myeloma

1 reference

12 December 2020

Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness

1 reference

12 December 2020

The unravelling of the ubiquitin system

1 reference

12 December 2020

10.1007/S12020-015-0682-Y

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26162929 AND SRC:MED&resulttype=core&format=json

19 February 2020

1 reference